<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>CUPRIC SULFATE - cupric sulfate injection, solution </strong><br>American Regent, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1><span class="Bold">CUPRIC SULFATE INJECTION, USP</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
<p><span class="Bold">STERILE, PYROGEN FREE, TRACE ELEMENT ADDITIVE</span></p>
<p><span class="Bold">FOR IV USE AFTER DILUTION</span></p>
<p><span class="Bold">(COPPER 0.4 mg/mL)</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First">Cupric Sulfate Injection, USP is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). Each mL contains Cupric Sulfate (Pentahydrate) 1.57 mg. It delivers elemental copper 0.4 mg/mL. The 10 mL vial is a single dose preservative free vial. Discard any unused portion.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First">Copper is essential as a cofactor for serum <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>, an oxidase necessary for proper formation of the iron carrier protein, transferrin. Copper also helps maintain normal rates of red and white blood cell formation. Scorbutic type bone changes seen in infants fed exclusively with copper-poor cow’s milk are believed due to <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span> of ascorbate oxidase, a cuproenzyme.</p>
<p>Providing copper during TPN prevents development of the following deficiency symptoms: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, depressed <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span> levels, impaired transferrin formation and secondary <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">Cupric Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First">Cupric Sulfate Injection, USP should not be given undiluted by direct injection into a peripheral vein because of the potential for infusion <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS
</span></h1>
<p class="First">This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.</p>
<p>Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<p class="First">Administration of copper in the absence of zinc may cause a decrease in plasma zinc levels. Periodic determinations of plasma zinc as well as copper are suggested as a guideline for subsequent copper administration. As copper is eliminated via the bile, the possibility of copper retention should be considered in patients with biliary tract obstruction. Decreasing or omitting copper supplements entirely may be necessary in such patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First">The amount of copper present in Cupric Sulfate Injection, USP is very small, symptoms from copper toxicity are considered unlikely to occur.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">Cupric Sulfate Injection, USP provides 0.4 mg copper/mL. For the metabolically stable adult receiving TPN, the suggested additive dosage level is 0.5 to 1.5 mg copper/day. For pediatric patients, the suggested additive dosage level is 20 mcg copper/kg/day.</p>
<p>Aseptic addition of Cupric Sulfate Injection, USP to the TPN solution under a laminar flow hood is recommended. Copper is physically compatible with the electrolytes and vitamins usually present in the amino acid/dextrose solution used for TPN. Weekly monitoring of copper plasma levels is suggested as a guideline for subsequent administration. The normal plasma range for copper is approximately 80 to 160 mcg/100 mL.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.</p>
<div class="Section">
<a name="section-9.1"></a><p></p>
<h2><span class="Bold">Use in Pregnancy
</span></h2>
<p class="First">Safety for use in pregnancy has not been established. Use of copper in women of childbearing potential requires that anticipated benefits be weighed against possible hazards.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">Symptoms of copper toxicity reported in the literature include <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">prostration</span>, behavior change, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, progressive marasmus, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. D-pencillamine has been reported effective as an antidote. Symptoms of overdosage from copper given at 1.5 mg/day are considered unlikely.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Cupric Sulfate Injection, USP (0.4 mg/mL)</p>
<p>NDC 0517-6210-25       10 Ml SDV       packed in a box of 25</p>
<p>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).</p>
<p><span class="Bold">AMERICAN</span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span><span class="Bold"><br></span><span class="Bold">SHIRLEY, NY 11967</span></p>
<p>IN6210</p>
<p>Rev. 1/09</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<p class="First">PRINCIPAL DISPLAY PANEL – 10 mL Carton</p>
<p><span class="Bold">CUPRIC SULFATE</span><br>INJECTION, USP</p>
<p><span class="Bold">Copper 4 mg/10 mL</span> (0.4 mg/mL)</p>
<p>Trace Element Additive</p>
<p><span class="Bold">NDC 0517-6210-25</span></p>
<p><span class="Bold">25 x 10 mL SINGLE DOSE VIALS</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE AFTER DILUTION</span></p>
<p><span class="Bold">PRESERVATIVE FREE</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Each mL contains: Cupric Sulfate (Pentahydrate) 1.57 mg, Water for Injection q.s.</p>
<p>pH adjusted with Sulfuric Acid when necessary. Sterile, nonpyrogenic.</p>
<p><span class="Bold">WARNING:</span> DISCARD UNUSED PORTION.</p>
<p>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).</p>
<p>Directions for Use: See Package Insert.</p>
<p><span class="Bold">AMERICAN REGENT, INC.</span><span class="Bold"><br></span>SHIRLEY, NY 11967</p>
<p>Rev. 11/05</p>
<div class="Figure"><img alt="dab399d9-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=941ad1e2-6052-4df4-8cfe-5af4a99703e4&amp;name=dab399d9-figure-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CUPRIC SULFATE 		
					</strong><br><span class="contentTableReg">cupric sulfate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-6210</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CUPRIC SULFATE</strong> (COPPER) </td>
<td class="formItem">CUPRIC SULFATE</td>
<td class="formItem">1.57 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-6210-25</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>American Regent, Inc.
							(622781813)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dab399d9-723e-4ef6-8ba7-c41ce2c1b48d</div>
<div>Set id: 941ad1e2-6052-4df4-8cfe-5af4a99703e4</div>
<div>Version: 1</div>
<div>Effective Time: 20111008</div>
</div>
</div> <div class="DistributorName">American Regent, Inc.</div></p>
</body></html>
